Latest Conference Articles

February 25th 2016, 3:23pm

Multidisciplinary Head and Neck Cancer Symposium

Renato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).

February 23rd 2016, 12:44pm

Multidisciplinary Head and Neck Cancer Symposium

An early-stage trial is examining the addition of nivolumab to a cetuximab regimen in head and neck squamous cell carcinoma.

February 23rd 2016, 6:56am

Multidisciplinary Head and Neck Cancer Symposium

The combination of pazopanib (Votrient) and cetuximab (Erbitux) showed a disease control rate of 77% in patients with recurrent or metastatic head and neck squamous cell carcinoma, including patients with cetuximab- or platinum-resistant disease.

February 22nd 2016, 12:42pm

Multidisciplinary Head and Neck Cancer Symposium

Among patients with HPV-negative, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis, adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control.

February 22nd 2016, 8:27am

Multidisciplinary Head and Neck Cancer Symposium

James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.

February 22nd 2016, 7:08am

Multidisciplinary Head and Neck Cancer Symposium

Renato G. Martins, MD, discusses the impact of lenvatinib in patients with differentiated thyroid cancer, how and when it should be used in clinical practice, and the future potential for the agent.

February 20th 2016, 3:19pm

Multidisciplinary Head and Neck Cancer Symposium

Maria E. Cabinillas, MD, associate professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses administering lenvatinib (Lenvima) as a first-line therapy for patients with differentiated thyroid cancer (DTC).

February 20th 2016, 12:38pm

Multidisciplinary Head and Neck Cancer Symposium

Both progression-free and overall survival with second-line afatinib (Gilotrif) in recurrent or metastatic head and neck squamous cell carcinoma are associated with several biomarkers.

February 20th 2016, 10:50am

Multidisciplinary Head and Neck Cancer Symposium

Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a study that examined the molecular profile of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC) stratified by smoking status.

February 20th 2016, 9:00am

Multidisciplinary Head and Neck Cancer Symposium

The use of induction chemotherapy for advanced head and neck squamous cell carcinoma does not improve overall survival.

February 19th 2016, 4:44pm

Multidisciplinary Head and Neck Cancer Symposium

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab's potential as a treatment of patients with head and neck cancer, as reported in the CheckMate-141 study.

February 19th 2016, 3:18pm

Multidisciplinary Head and Neck Cancer Symposium

Patients with locally advanced head and neck cancer should be screened for social isolation and financial hardship, as these factors play a role in their ability to stay on medication, minimize hospital stays, and achieve optimal health outcomes.

February 19th 2016, 3:08pm

Multidisciplinary Head and Neck Cancer Symposium

Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer.

February 19th 2016, 8:51am

Multidisciplinary Head and Neck Cancer Symposium

In patients treated with definitive radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma, most recurrences can be detected via imaging at 3 months and physical examinations during the first 6 months after treatment.

February 19th 2016, 7:55am

Multidisciplinary Head and Neck Cancer Symposium

Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the impact of immunotherapy agents as treatment of patients with head and neck cancer.

February 19th 2016, 6:03am

Multidisciplinary Head and Neck Cancer Symposium

Concurrent chemoradiation significantly improved overall survival compared with radiation therapy alone for elderly patients with locally advanced head and neck cancers.

February 18th 2016, 3:40pm

Multidisciplinary Head and Neck Cancer Symposium

Ezra Cohen, MD, associate director, Moores Cancer Center, professor of Medicine, University of California, San Diego Health System, discusses tumor biomarker association with clinical outcomes in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with afatinib versus methotrexate.

February 18th 2016, 2:57pm

Multidisciplinary Head and Neck Cancer Symposium

Tobacco-associated mutations accumulate over time in smokers with HPV-positive oropharyngeal squamous cell cancer, resulting in less dependence on E6/E7 and other HPV-associated mutations.

January 26th 2016, 12:43pm

Gastrointestinal Cancers Symposium (ASCO GI)

Mismatch repair-deficient gastrointestinal tumors are highly responsive to checkpoint blockade with anti-PD-1 therapy.

January 26th 2016, 9:13am

Gastrointestinal Cancers Symposium (ASCO GI)

A potential biomarker to guide chemotherapy for metastatic colorectal cancer failed to stratify patients by progression-free survival or responsiveness to bevacizumab.